Warfarin Another Option for Cancer-Associated Thrombosis

Article

Warfarin is an acceptable alternative to low-molecular-weight heparin for patients with cancer-associated thrombosis, according to a new study.

Warfarin is an acceptable alternative to low-molecular-weight heparin (LMWH) for patients with cancer-associated thrombosis, according to a new study.

LMWH is considered to be the anticoagulation of choice for the treatment of cancer-associated thrombosis. However, there are little data to support the best ongoing anti-clotting therapy beyond 6 months, said lead author Chatree Chai-Adisaksopha, MD, of McMaster University in Hamilton, Ontario, Canada.

Dr. Chai-Adisaksopha presented the results at the 57th Annual American Society of Hematology (ASH) Meeting and Exposition, held December 5–8 in Orlando, Florida (abstract 430).

Dr. Chai-Adisaksopha and colleagues conducted a study to evaluate the efficacy and safety of warfarin vs LMWH in patients treated with an initial course of 6 months of therapy. They performed a retrospective analysis of 1,502 consecutive patients enrolled in a registry. The patients had objectively proven venous thromboembolism with active cancer and were planned to be treated with LMWH for 6 months.

They divided the patients into two groups at 6 months after diagnosis: one group of 763 patients continued to receive LMWH and the other group of 739 patients was switched to warfarin. Because LMWH requires self-injections, warfarin is often thought to be preferred because it is an oral medication, he said.

After a median 11 months follow-up, recurrent venous thromboembolism was apparent in 55 patients (7.2%) who continued to receive LMWH and in 44 patients (6%) who switched to warfarin. The cumulative incidence of major bleeding was 2.6% in the LMWH group and 2.7% in the warfarin group.

“The main outcome-recurrent venous thromboembolism-shows that there was no statistical difference between the two groups,” Dr. Chai-Adisaksopha said.

In conclusion, he said that the study found that switching to warfarin is not associated with an increase in recurrent venous thromboembolism, major bleeding, or total bleeding when compared to continuing LMWH. Therefore, the researchers believe that warfarin is an acceptable alternative to LMWH for patients with cancer-associated thrombosis.

Dr. Chai-Adisaksopha added that this finding needs to be confirmed in a prospective study.

Recent Videos
Treatment with CAR T cells may allow patients with hematologic malignancies to recover more quickly compared with a transplant, says Andre Goy, MD.
In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.
Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center .
Amitkumar Mehta, MD, detailed encouraging data presented at the 63rd ASH Annual Meeting for treating mantle cell lymphoma.
Michael R. Bishop, MD, discussed details from the ZUMA-7 and TRANSFORM trials that were presented at the 63rd ASH Annual Meeting.
Yael Cohen, MD, sat down with CancerNetwork® to discuss how the multiple myeloma space is entering into an era of CAR T-cell therapy.
Yael Cohen, MD, discusses safety data from a clinical trial assessing the use of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.
In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.
Jakubowiak on Future Promise of Cilta-Cel Across Settings in Multiple Myeloma at 2021 ASH
Related Content